Ticker
ABBV

Price
153.67
Stock movement down
-3.10 (-1.98%)
Company name
AbbVie Inc
Exchange
(NYSE
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers-General
Capitalisation boursière
271.76B
Valeur d'entreprise
385.23B
Cours/chiffre d'affaires
4.70
Cours/valeur comptable
16.96
Rendement du div
3.85%
Croissance du div
17.11%
Années de croissance
9
Versement FCF
44.94%
Trailing P/E
20.27
P/E prévisionnel
13.09
PEG
2.45
Croissance EPS
36.80%
Rendement sur 1 an
-3.99%
Rendement sur 3 ans
30.70%
Rendement sur 5 ans
6.41%
Rendement sur 10 ans
14.89%
Dernière modification : 2023-03-22
Get the latest news and real-time alerts from AbbVie Inc. (ABBV) stock at Seeking Alpha.
28 mars 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from AbbVie Inc. (ABBV) stock at Seeking Alpha.
23 mars 2023

iO Charts is a Seeking Alpha partner

ANALYSE DU MARCHE

Revenues per Product Category ($M)

Loading...
Company comments

AbbVie was created through a spinoff from Abbott Laboratories in 2013

Humira is the world’s #1 global pharmaceutical product by a large margin

AbbVie acquired Allergan, the maker of Botox in 2020, hence the huge jump in revenues and the change in the segment classifications

Geographic Revenues ($M)

Loading...

DIVIDENDES

Rendement du dividende - 5 ans

Loading...
Données du rendement du dividende
Dividende par action5.92
Rendement du dividende3.85%
Fréquence de versementTrimestriel
Rendement maximum7.32%
Rendement moyen4.74%
Rendement minimum3.22%
Escompte sur rendement moyen-23.12%
Potentiel de hausse-18.78%
Rendement comme % du rendement max52.64%

Distribution des rendements (percentile inversé) - 5 ans

Loading...
Données de distribution des rendements
Rendement du dividende3.85%
Distribution des rendements actuels86.19%
Rendement à 100 % (min)3.22%
Rendement à 90 %3.77%
Rendement à 80 %3.95%
Rendement à 50 % (moyen)4.80%
Rendement à 20 %5.39%
Rendement à 10 %5.77%
Rendement à 0 % (max)7.32%

Dividende par action

Loading...
Données du dividende par action
Années de croissance9 years
Statut CCCDividend Challenger
Dividende par action5.92
Fréquence de versementTrimestriel
Date ex-div13 Apr 2023
EPS (TTM)7.55
EPS (prévision sur 1 an)11.74
Croissance EPS (5 ans)36.80%
Croissance EPS (prévision sur 5 ans)8.27%

Croissance du dividende

Loading...
Créez un compte gratuit ou connectez-vous pour accéder à ce graphique
Données de croissance du dividende
ABBVS&P500
DGR MR4.96%-15.45%
DGR TTM6.64%11.27%
DGR 3 ans9.63%4.00%
DGR 5 ans17.11%5.65%
DGR 10 ans-7.37%
DGR 15 ans-5.83%
Délai depuis le dernier changement annoncé155 days
Croissance EPS (5 ans)36.80%
Croissance EPS (prévision sur 5 ans)8.27%

Ratio de versement

Loading...
Créez un compte gratuit ou connectez-vous pour accéder à ce graphique
Données du ratio de versement
Couverture EPSCouverture FCF
TTM73.48%44.94%
Moyenne--
Prévision50.43%-
Get the latest news and real-time alerts from AbbVie Inc. (ABBV) stock at Seeking Alpha.
23 mars 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from AbbVie Inc. (ABBV) stock at Seeking Alpha.
23 mars 2023

iO Charts is a Seeking Alpha partner

VALORISATION

Ratios de valorisation

Loading...
Données de ratios de valorisation
Trailing P/E20.27
Cours/OCF12.03
Cours/FCF12.40
Cours/EBITDA10.74
EV/EBITDA15.23

Valorisation (Chiffre d'affaires/valeur comptable)

Loading...
Données de valorisation (Chiffre d'affaires/valeur comptable)
Cours/chiffre d'affaires4.70
Cours/valeur comptable16.96
EV/chiffre d'affaires6.66
Get the latest news and real-time alerts from AbbVie Inc. (ABBV) stock at Seeking Alpha.
22 mars 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from AbbVie Inc. (ABBV) stock at Seeking Alpha.
22 mars 2023

iO Charts is a Seeking Alpha partner

DONNEES FINANCIERES

Par action

Loading...
Données par action
Nombre d'actions actuel1.77B
EPS (TTM)7.55
FCF par action (TTM)12.34

Compte de résultat

Loading...
Données du compte de résultat
Revenu (TTM)57.82B
Bénéfice brut (TTM)40.26B
Résultat d'exploitation (TTM)17.69B
Résultat net (TTM)13.41B
EPS (TTM)7.55
EPS (prévision sur 1 an)11.74

Marges

Loading...
Données des marges
Marge brut (TTM)69.62%
Marge d'exploitation (TTM)30.59%
Marge bénéficiaire (TTM)23.19%

Bilan comptable

Loading...
Créez un compte gratuit ou connectez-vous pour accéder à ce graphique
Données du bilan comptable
Trésorerie11.83B
Créances nettes10.74B
Total de l'actif à court terme30.36B
Ecart d'acquisition31.73B
Immobilisations incorporelles68.72B
Immobilisations corporelles0.00
Total de l'actif141.32B
Comptes fournisseurs23.50B
Dette à court/long terme69.61B
Total du passif à court terme32.71B
Total du passif125.30B
Capitaux propres16.03B
Valeur nette des immobilisations corporelles-84.46B

Flux de trésorerie

Loading...
Créez un compte gratuit ou connectez-vous pour accéder à ce graphique
Données du flux de trésorerie
Flux de trésorerie d'exploitation (TTM)22.59B
Dépenses en capital (TTM)669.00M
Flux de trésorerie disponible (TTM)21.92B
Dividendes versés (TTM)9.85B

Rendements financiers

Loading...
Créez un compte gratuit ou connectez-vous pour accéder à ce graphique
Données de rendements financiers
Rendement des capitaux propres83.65%
Rendement des actifs9.49%
Rendement du capital investi15.66%
Rendement en espèces du capital investi25.60%
AbbVie Inc. (NYSE:NYSE:ABBV) Barclays Global Healthcare Conference Call March 15, 2023 1:35 PM ETCompany ParticipantsRobert Michael - Vice Chairman & PresidentScott Reents - Senior Vice...
15 mars 2023

iO Charts is a Seeking Alpha partner

AbbVie is one of the most prominent biotechnology/healthcare stocks known for paying a good dividend. See why I rate ABBV stock a hold.
14 mars 2023

iO Charts is a Seeking Alpha partner

INFORMATIONS SUR LES ACTIONS

Graphique boursier

Loading...
Données du prix des actions
Ouverture155.68
Max journalier156.88
Min journalier153.61
Volume journalier4.37M
Niveau record174.96
Estimation des analystes sur 1 an162.50
Beta0.62
EPS (TTM)7.55
Dividende par action5.92
Date ex-div13 Apr 2023
Prochaine date de bénéfices27 Apr 2023

Potentiel de baisse

Loading...
Données du potentiel de baisse
ABBVS&P500
Baisse de prix actuelle par rapport au niveau record-12.17%-17.92%
Baisse de prix actuelle la plus importante-48.88%-56.47%
Date de la baisse la plus importante15 Aug 20199 Mar 2009
Baisse moyenne par rapport au record-14.20%-11.51%
Délai moyen pour nouveau record17 days13 days
Délai max pour nouveau record975 days1805 days
AbbVie is down about 8% YTD and appears undervalued at 13 times earnings. Learn more about ABBV stock here.
14 mars 2023

iO Charts is a Seeking Alpha partner

AbbVie's Humira sales may hold up better against biosimilars in the USA than they have in Europe. Find out if ABBV stock is a buy at current levels.
14 mars 2023

iO Charts is a Seeking Alpha partner

INFORMATIONS SUR LA SOCIETE
ABBV (AbbVie Inc) company logo
Capitalisation boursière
271.76B
Catégorie de capitalisation boursière
Large-cap
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Employés
50000
Communication financière
Dossiers SEC
CEO
Richard Gonzalez
Pays
USA
Ville
North Chicago
Type d'action
Common stock
Statut CCC
Dividend Challenger
Fréquences des dividendes
Trimestriel
EVENEMENTS ET PRESENTATIONS
EvénementsPrésentations
Loading...
With the collapse of SVB Financial Group dominating the news, we should look at recession-resilient companies like AbbVie. See why ABBV stock is a Buy.
14 mars 2023

iO Charts is a Seeking Alpha partner

While the market has a case of the jitters, AbbVie stock has a calming effect. Read more to examine why and whether ABBV stock is still a quality buy.
13 mars 2023

iO Charts is a Seeking Alpha partner

COMPRENDRE LE METIER
Loading...
Get the latest news and real-time alerts from AbbVie Inc. (ABBV) stock at Seeking Alpha.
13 mars 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from AbbVie Inc. (ABBV) stock at Seeking Alpha.
12 mars 2023

iO Charts is a Seeking Alpha partner

ACTUALITES DE LA SOCIETE
Toute l'actualitéCommuniqués de presse
A common misconception is that you need a lot of money to invest in the stock market. Let's look at three healthcare stocks that can be purchased for $100 and have good prospects to grow over time. ...
31 mars 2023
AbbVie (NYSE: ABBV) recently shared positive top-line results from its phase 3 clinical trial of Skyrizi that treated patients with moderately to severely active ulcerative colitis (UC). Let's examin...
31 mars 2023
In this article, we will take a look at the 15 safe stocks to buy. To see more such companies, go directly to Starter Stock Portfolio: 5 Safe Stocks To Buy. Amid the current market turmoil which seems...
30 mars 2023
In this article, we will take a look at the 12 most promising healthcare stocks according to analysts. To see more such companies, go directly to 5 Most Promising Healthcare Stocks According to Analys...
29 mars 2023
Vertex Pharmaceuticals (NASDAQ: VRTX) and AbbVie (NYSE: ABBV) both beat last year's bear market. Vertex and AbbVie also happen to offer a lot of growth potential. Vertex has a new potential blockbus...
29 mars 2023
Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, will be showcasing its customer-centric 'Discover Your 360°' approach to aesthetics at the 21st Anti-Aging and Aesthetics Medicine World Congress (...
29 mars 2023
AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) are two of the world's biggest pharmaceutical companies, and the similarities don't end there. The case for AbbVie as a growth stock can't avoid two issues:...
29 mars 2023
CytomX Therapeutics Inc (NASDAQ: CTMX) will weigh its options for CX-2029, a CD71-directed antibody-drug conjugate, after AbbVie Inc (NYSE: ABBV) decided not to advance the drug into additional studie...
28 mars 2023
While there's no ironclad method for picking perfectly safe stocks, thankfully there are a few dividend-paying companies that are a bit less risky than average -- as a result of their history of effec...
28 mars 2023
The Schwab U.S. Dividend ETF (NYSEMKT: SCHD) just went through its annual reconstitution, meaning the top positions look different than they did just a few weeks prior. AbbVie (NYSE: ABBV) is now the ...
28 mars 2023
Page suivante
Get the latest news and real-time alerts from AbbVie Inc. (ABBV) stock at Seeking Alpha.
10 mars 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from AbbVie Inc. (ABBV) stock at Seeking Alpha.
9 mars 2023

iO Charts is a Seeking Alpha partner